AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB · NASDAQ Global Market
+$0.25 today
Vol 0.19M · Avg 0.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.0%
avg 0.0%
ROIC
0.0%
avg 0.0%
ROA
0.0%
avg 0.0%
Analysis
ROE is currently the strongest return metric at 0.0% versus its period average of 0.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrea Sáez Borderías | Chief Development Officer | — | — | 44 | — | — |
Philippe Wiesel | Chief Medical Officer | — | — | 59 | — | — |
Tim Knotnerus | CEO & Executive Director | — | — | 43 | — | — |
Paolo Michieli | Founder, Senior Advisor & Member of Scientific Advisory Board | — | — | — | — | — |
Pierre Kemula | Chief Financial Officer | — | — | 52 | — | — |
Ellen Lefever | General Counsel | — | — | 41 | — | — |
Sofie Van Gijsel | Vice President of Investor Relations | — | — | — | — | — |
Paul Van Der Horst | Chief Business Officer | — | — | 38 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages AGMB?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) lists 8 active executives. The top listed executive is Andrea Sáez Borderías, Chief Development Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.